{"pmid":32361195,"title":"SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?","text":["SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?","Autoimmun Rev","Prete, Marcella","Favoino, Elvira","Catacchio, Giacomo","Racanelli, Vito","Perosa, Federico","32361195"],"journal":"Autoimmun Rev","authors":["Prete, Marcella","Favoino, Elvira","Catacchio, Giacomo","Racanelli, Vito","Perosa, Federico"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361195","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102559","keywords":["autoinflammatory syndrome","caps","capillary leakage syndrome","il-6","ivig","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495915130880,"score":9.490897,"similar":[{"pmid":32363963,"title":"Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case-report.","text":["Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case-report.","J Dermatolog Treat","Daneshpazhooh, Maryam","Soori, Tahereh","Isazade, Ahdie","Noormohammadpour, Pedram","32363963"],"journal":"J Dermatolog Treat","authors":["Daneshpazhooh, Maryam","Soori, Tahereh","Isazade, Ahdie","Noormohammadpour, Pedram"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363963","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/09546634.2020.1764472","keywords":["covid-19","ivig","mucous membrane pemphigoid"],"topics":["Case Report"],"weight":1,"_version_":1666138496060882944,"score":98.705734},{"pmid":32218340,"pmcid":"PMC7178250","title":"Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?","text":["Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?","The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen Candida albicans in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 degrees C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available.","Int J Mol Sci","Jawhara, Samir","32218340"],"abstract":["The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen Candida albicans in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 degrees C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available."],"journal":"Int J Mol Sci","authors":["Jawhara, Samir"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32218340","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.3390/ijms21072272","keywords":["ivig","coronavirus","immunotherapy","ncov-2019","virus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138492290203648,"score":79.24783},{"pmid":32432784,"title":"Editorial - High dose intravenous immunoglobulins as a therapeutic option for COVID-19 patients.","text":["Editorial - High dose intravenous immunoglobulins as a therapeutic option for COVID-19 patients.","Eur Rev Med Pharmacol Sci","Scoppetta, C","Di Gennaro, G","Polverino, F","32432784"],"journal":"Eur Rev Med Pharmacol Sci","authors":["Scoppetta, C","Di Gennaro, G","Polverino, F"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32432784","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.26355/eurrev_202005_21214","topics":["Treatment"],"weight":1,"_version_":1667342288299229184,"score":70.38845},{"pmid":32413374,"title":"Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients - a perspective.","text":["Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients - a perspective.","J Allergy Clin Immunol","Hammarstrom, Lennart","Abolhassani, Hassan","Baldanti, Fausto","Marcotte, Harold","Pan-Hammarstrom, Qiang","32413374"],"journal":"J Allergy Clin Immunol","authors":["Hammarstrom, Lennart","Abolhassani, Hassan","Baldanti, Fausto","Marcotte, Harold","Pan-Hammarstrom, Qiang"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413374","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jaci.2020.04.043","keywords":["covid-19","ivig","immunodeficiency","monoclonal antibody","passive immunity","plasma therapy"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319176437760,"score":60.443127},{"pmid":32196410,"pmcid":"PMC7170333","title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.","text":["Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.","Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed.","Emerg Microbes Infect","Lin, Ling","Lu, Lianfeng","Cao, Wei","Li, Taisheng","32196410"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed."],"journal":"Emerg Microbes Infect","authors":["Lin, Ling","Lu, Lianfeng","Cao, Wei","Li, Taisheng"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196410","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1746199","keywords":["covid-19","ivig","sars-cov-2","anticoagulation","pathogenesis"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Heparin"],"topics":["Mechanism"],"weight":1,"_version_":1666138489986482176,"score":59.49919}]}